论文部分内容阅读
探讨放疗联合CIK对中晚期恶性肿瘤患者的疗效。62例经病理或临床诊断为中晚期恶性肿瘤的患者,按治疗方法不同分为单纯组与联合组,每组各31例,单纯组仅接受放射治疗,联合组接受放疗联合CIK治疗,检测其治疗前后外周血T细胞亚群比例的变化,影像学检查评价近期疗效。与单纯组相比,联合组患者细胞免疫功能较之前明显改善,其中CD3~+T细胞、CD4~+T细胞、CD4~+T细胞/CD8~+T细胞较治疗前明显升高(P均<0.05)。近期疗效评价显示,两组客观缓解率无显著差异(25.8%vs 29.0%,P=0.662),但联合组疾病控制率较对照组明显提高(67.7%vs 83.9%,P=0.048)。放疗联合CIK治疗可有效提高中晚期恶性肿瘤患者T淋巴细胞免疫功能、控制肿瘤生长、改善生活质量。
To investigate the efficacy of radiotherapy combined with CIK on patients with advanced malignant tumors. Sixty-two patients with pathologically or clinically diagnosed advanced malignant neoplasms were divided into simple group and combination group according to different treatment methods. Each group consisted of 31 patients. The simple group received radiotherapy only. The combined group received radiotherapy combined with CIK. Changes in the proportion of T cell subsets in peripheral blood before and after treatment, imaging evaluation of short-term efficacy. Compared with the simple group, the cellular immune function in the combined group was significantly improved compared with that before, in which CD3 ~ + T cells, CD4 ~ + T cells and CD4 ~ + T cells / CD8 ~ + T cells were significantly increased <0.05). The recent curative effect evaluation showed that there was no significant difference between the two groups (25.8% vs 29.0%, P = 0.662). However, the control rate of the combined group was significantly higher than that of the control group (67.7% vs 83.9%, P = 0.048). Radiotherapy combined with CIK treatment can effectively improve the immune function of T lymphocytes in patients with advanced cancer, control tumor growth and improve quality of life.